Are Wall Street Analysts Predicting Intuitive Surgical Stock Will Climb or Sink?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 26 2024
0mins
Source: NASDAQ.COM
Company Overview and Performance: Intuitive Surgical, Inc. specializes in robotic-assisted surgical systems and has seen significant stock performance, gaining 68.7% over the past year compared to the S&P 500's 31.3%. The company reported strong Q3 earnings with a revenue increase of 17% year-over-year.
Analyst Ratings and Future Outlook: Analysts maintain a "Moderate Buy" consensus on ISRG stock, with expectations for a 34.6% EPS growth this fiscal year. Recent upgrades from analysts suggest potential price targets indicating further upside for investors.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ISRG is 637.32 USD with a low forecast of 575.00 USD and a high forecast of 740.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 525.810
Low
575.00
Averages
637.32
High
740.00
Current: 525.810
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
